NCT02727764View on ClinicalTrials.gov

A Single Dose Clinical Trial to Study the Safety of ART-I02 in Patients With Arthritis

PHASE1UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 20, 2017

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Arthritis, RheumatoidOsteo Arthritis
Interventions
GENETIC

ART-I02

Single Intra-articular injection in the carpometacarpal (CMC), metacarpophalangeal (MCP), proximal interphalangeal (PIP), or distal interphalangeal (DIP) joint

Trial Locations (1)

Unknown

Centre for Human Drug Research (CHDR), Leiden

Sponsors

Lead Sponsor

Arthrogen
All Listed Sponsors
collaborator

Centre for Human Drug Research (CHDR)

UNKNOWN

lead

Arthrogen

INDUSTRY

NCT02727764 - A Single Dose Clinical Trial to Study the Safety of ART-I02 in Patients With Arthritis | Biotech Hunter | Biotech Hunter